Español Deutsch English Become a Fan of our online pharmacy and get 3€. Get Your Discount Code Here.
Latest News
News Categories
Most Popular Tags
Compra Segura
Compra Segura
News and Site Information. HEADING_TITLE
No new conclusions on Avandia yet
Date: Tuesday 23 February, 2010
The U.S. Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline Plc's diabetes drug Avandia but has not reached any conclusions, the agency said on Monday. No new conclusions on Avandia yet


The FDA will hold a public meeting in July 2010 to discuss risks and benefits of the drug, but said in the meantime doctors and patients should continue to use Avandia as directed.

"This work is ongoing and no new conclusions or recommendations about the use of rosiglitazone (Avandia) in the treatment of type 2 diabetes have been made at this time," the FDA said, referring to the drug's generic name.

On Saturday, two U.S. senators released a report on Avandia and internal FDA documents. The documents included a 2008 memo from two FDA drug safety reviewers who recommended pulling the drug from the U.S. market after they concluded it was more dangerous to the heart than the rival drug Actos by Takeda Pharmaceutical Co Ltd.

One of the reviewers, FDA critic David Graham, had argued to an advisory panel in 2007 that Avandia should no longer be sold. That panel voted 22-1 to recommend the drug remain on the market.

Glaxo shares fell 2.5 percent to close at $37.32 on the New York Stock Exchange on Monday. Analysts said new attacks on Avandia could add to litigation risks and help rival drugmakers.

Sales of Avandia topped $3 billion in 2006, but fell to $1.2 billion in 2009.

The FDA said on Monday it is reviewing data from a Glaxo-sponsored study known as Record, as well as other studies that look at the cardiovascular safety of Avandia. The FDA will present all of the safety data at a public advisory panel meeting in July.

The FDA decided in November 2007 Avandia should carry a warning saying a review of 42 studies associated the drug with an increased risk of a heart attack or chest pain compared with a placebo. But it said overall data were "inconclusive."

"We don't find that available information since that time has really changed the assessment," Dr. Janet Woodcock, head of the FDA's drugs center, said on a conference call with doctors on Monday.

Woodcock added, "We feel that it is time for a thorough re-evaluation of all the data of the drug as far as cardiovascular risk, and we are undertaking that right now."



Article Statistics:
Viewed:1535

Customer Reviews (0)

No hay comentarios todav�a. S� el primero!

Publicar un comentario nuevo


CAPTCHA ImageCambiar Imagen
Print View Continue
New Products in August
Alvita Reconstructive Hand Cream 100ml by Alvita
Alvita Reconstructive Hand Cream 100ml 1.95€
+ Info
Alvita Revitalizing Shampoo 300ml by Alvita
Alvita Revitalizing Shampoo 300ml 2.49€
+ Info
ThermaCare Neck, Wrist & Shoulder by Pfizer
ThermaCare Neck, Wrist & Shoulder 5.61€
+ Info
Philips AVENT Digital baby thermometer set SCH540/00 by Avent
Philips AVENT Digital baby thermometer set SCH540/00 29.46€
+ Info
Featured Product
Salises Cream Gel Cream 50ml

Salises Cream Gel Cream 50ml
34.49€
Clearblue Easy Digital Ovulation Test

Clearblue Easy Digital Ovulation Test
34.71€
22.99€
Emjoi Micro-Pedi

Emjoi Micro-Pedi
49.97€
39.95€
Tensoval duo control

Tensoval duo control
122.10€
69.96€
Sesderma C-Vit Radiance Glowing Fluid 50ml

Sesderma C-Vit Radiance Glowing Fluid 50ml
27.72€
Fertilcontrol Easy Ovulation Monitor Device.

Fertilcontrol Easy Ovulation Monitor Device.
35.49€
30.72€
Rss
Like us Like us Follow us Follow us Watch Us Watch Us Follow us Follow us Join Us Join Us Follow us Follow us
Visa Mastercard Tick icon
Copyright © 2014 Farmacia La Nucia
Powered by osCommerce